Literature DB >> 9690138

Loricrin and human skin diseases: molecular basis of loricrin keratodermas.

A Ishida-Yamamoto1, H Takahashi, H Iizuka.   

Abstract

The cornified cell envelope (CE) is a tough structure formed beneath the plasma membrane of terminally differentiated keratinocytes. Recent progress in understanding the molecular organization of the CE has disclosed the complex, yet orderly structure that functions as a protective barrier against the environment. We have recently demonstrated that two inherited skin diseases, Vohwinkel's syndrome (VS) and progressive symmetric erythrokeratoderma (PSEK) may result from mutations in the gene encoding loricrin, a major constituent of the CE. In adult human epidermis, loricrin is diffusely distributed within the superficial granular cells. In the cornified cells, loricrin is associated with CEs. In some patients with VS and PSEK skin, however, granular cells contain many intranuclear granules which are labeled with an amino-terminal loricrin antibody. CEs are thinner than normal and sparsely labeled with the loricrin antibody. Parakeratotic cornified cells contain loricrin-positive granules. Sequencing of the loricrin gene has disclosed heterozygous mutations; insertion of one nucleotide (730insG, 709insC) that shifts the reading frame in these patients. Consequently the carboxyl-terminus are replaced by highly charged missense sequences that override the endogeneous termination codon extending the protein with an additional 22 amino acids. Elucidation of the molecular biology of "loricrin keratodermas" adds to our understanding of the complexity and biological significance of the CE.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690138     DOI: 10.14670/HH-13.819

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  8 in total

1.  Embryonic AP1 Transcription Factor Deficiency Causes a Collodion Baby-Like Phenotype.

Authors:  Christina A Young; Richard L Eckert; Gautam Adhikary; Debra Crumrine; Peter M Elias; Miroslav Blumenberg; Ellen A Rorke
Journal:  J Invest Dermatol       Date:  2017-05-16       Impact factor: 8.551

2.  Activation of vascular endothelial growth factor receptor 2 in a cellular model of loricrin keratoderma.

Authors:  Kozo Yoneda; Toshio Demitsu; Kozo Nakai; Tetsuya Moriue; Wataru Ogawa; Junsuke Igarashi; Hiroaki Kosaka; Yasuo Kubota
Journal:  J Biol Chem       Date:  2010-03-17       Impact factor: 5.157

3.  Evaluation of the Efficacy of Loricrin as a Diagnostic Marker in Patients with Oral Submucous Fibrosis.

Authors:  Niva Mahapatra; Kailash C Dash; Lipsa Bhuyan; Abikshyeet Panda; Shyam S Behura; Pallavi Mishra
Journal:  J Pharm Bioallied Sci       Date:  2020-08-28

4.  Suppressing AP1 factor signaling in the suprabasal epidermis produces a keratoderma phenotype.

Authors:  Ellen A Rorke; Gautam Adhikary; Christina A Young; Dennis R Roop; Richard L Eckert
Journal:  J Invest Dermatol       Date:  2014-08-22       Impact factor: 8.551

5.  Progressive symmetric erythrokeratoderma with unusual associations.

Authors:  Ram Chander; Masarat Jabeen; Meenu Barara; Dinesh Kataria
Journal:  Indian J Dermatol       Date:  2014-05       Impact factor: 1.494

6.  Lessons from loricrin-deficient mice: compensatory mechanisms maintaining skin barrier function in the absence of a major cornified envelope protein.

Authors:  P J Koch; P A de Viragh; E Scharer; D Bundman; M A Longley; J Bickenbach; Y Kawachi; Y Suga; Z Zhou; M Huber; D Hohl; T Kartasova; M Jarnik; A C Steven; D R Roop
Journal:  J Cell Biol       Date:  2000-10-16       Impact factor: 10.539

Review 7.  Loricrin - an overview.

Authors:  S Nithya; T Radhika; Nadeem Jeddy
Journal:  J Oral Maxillofac Pathol       Date:  2015 Jan-Apr

8.  Complex Gene Loss and Duplication Events Have Facilitated the Evolution of Multiple Loricrin Genes in Diverse Bird Species.

Authors:  Anthony C Davis; Matthew J Greenwold; Roger H Sawyer
Journal:  Genome Biol Evol       Date:  2019-03-01       Impact factor: 3.416

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.